Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

Recruiting now

Conditions studied: Prostate Carcinoma

In brief

This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.

Key facts

Study ID

NCT07645391

Run by

University of Michigan Rogel Cancer Center

People needed

200

Starts

2017-01-01

Expected to finish

2030-01-01

Last updated by the study team

2026-06-12

Who can join

Age: 35 and older, up to 70. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• * Age 35-70 years
• Capable of providing informed consent
• Prognosis of > 5 years if affected by another cancer
• Patients need one to meet at least one of the following high genetic risk categories:
• Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53
• Carrier of mutation in a suspected PCa-related gene: e.g., ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, HOXB13
• Obligate carriers of the above mutations (e.g. their sisters/daughters have known mutations)
• Men with any family history of above mutation
• Family history of breast, prostate, or ovarian cancer in at least 2 individuals, or in 1 individual diagnosed before age 50

You may not qualify if…

• * Anuria
• Prior diagnosis or treatment for PCa
• Failure to provide informed consent
• Life expectancy < 5 years

Where it is running

• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.